Identification and Characterization of a Novel Human Sphingosine-1-phosphate Phosphohydrolase, hSPP2*

Chie Ogawa, Akio Kihara, Maiko Gokoh, and Yasuyuki IgarashiDagger

From the Department of Biomembrane and Biofunctional Chemistry, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-choume, Kita-ku, Sapporo 060-0812, Japan

Received for publication, September 17, 2002, and in revised form, October 22, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Sphingosine 1-phosphate (S1P) is a bioactive lipid molecule that acts as both an extracellular signaling mediator and an intracellular second messenger. S1P is synthesized from sphingosine by sphingosine kinase and is degraded either by S1P lyase or by S1P phosphohydrolase. Recently, mammalian S1P phosphohydrolase (SPP1) was identified and shown to constitute a novel lipid phosphohydrolase family, the SPP family. In this study we have identified a second human S1P phosphohydrolase, SPP2, based on sequence homology to human SPP1. SPP2 exhibited high phosphohydrolase activity against S1P and dihydrosphingosine 1-phosphate. The dihydrosphingosine-1-phosphate phosphohydrolase activity was efficiently inhibited by excess S1P but not by lysophosphatidic acid, phosphatidic acid, or glycerol 3-phosphate, indicating that SPP2 is highly specific to sphingoid base 1-phosphates. Immunofluorescence microscopic analysis demonstrated that SPP2 is localized to the endoplasmic reticulum. Although the enzymatic properties and localization of SPP2 were similar to those of SPP1, the tissue-specific expression pattern of SPP2 was different from that of SPP1. Thus, SPP2 is another member of the SPP family that may play a role in attenuating intracellular S1P signaling.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Sphingosine 1-phosphate (S1P),1 a sphingolipid metabolite, regulates diverse biological processes including mitogenesis, differentiation, migration, and apoptosis both as an extracellular mediator and as an intracellular second messenger (1-3). Extracellular effects of S1P are known to be mediated via the endothelial differentiation gene (Edg) family of plasma membrane G-protein-coupled receptors, whereas its intracellular targets have yet to be determined (2, 3). S1P is synthesized by the phosphorylation of sphingosine and catalyzed by sphingosine kinase. Once formed, S1P is rapidly degraded by S1P lyase to hexadecenal and phosphoethanolamine or dephosphorylated by S1P phosphohydrolase.

The existence of a S1P-specific phosphohydrolase had been suggested by biochemical analyses using cultured skin fibroblasts and rat liver (4, 5). In 2000, murine S1P phosphohydrolase (mSPP1) was cloned as a S1P phosphohydrolase based on sequence homology to the yeast sphingoid base 1-phosphate phosphatase, Lcb3p/Lbp1p/Ysr2p (6). Recently, a human homolog of mSPP1, hSPP1, which exhibits 76% identity and 81% similarity to mSPP1, was identified (7). These mammalian SPP1s and their two yeast homologs, Lcb3p and Ysr3p, constitute the SPP family, which is distinct from another lipid phosphohydrolase family, the type 2 lipid phosphate phosphohydrolases (LPP), both in sequence and in biochemical properties. Accordingly, the SPP family members are highly specific to sphingoid base 1-phosphates, including S1P, dihydrosphingosine 1-phosphate (dihydro-S1P), and phytosphingosine 1-phosphate (6-9); yet the LPP family members have broad substrate specificities including S1P, phosphatidate (PA), lysophosphatidate (LPA), ceramide 1-phosphate, and diacylglycerol pyrophosphate (10-14). Proteins from both the SPP and LPP families contain the following three conserved motifs: motif 1, KXXXXXXRP; motif 2, PSGH; and motif 3, SRXXXXXHXXXD. These motifs are found in a superfamily of phosphatases that include several lipid phosphatases, glucose-6-phosphatases, bacterial nonspecific acid phosphatases, and chloroperoxidase (15). The crystal structure of chloroperoxidase disclosed that these conserved motifs were in close proximity and that together they constituted a binding pocket for the cofactor vanadate, a compound structurally similar to phosphate (16). Thus, these motifs are believed to constitute the active site in members of this phosphatase superfamily, a conclusion supported by mutational analyses of yeast Dpp1p and mammalian LPP-1 (17, 18).

We report here that we have identified a second human S1P phosphohydrolase, termed hSPP2, based on sequence homology to hSPP1. hSPP2 exhibited high phosphohydrolase activity specifically against sphingoid base 1-phosphates. Additionally, in contrast to the ubiquitous expression of hSPP1, the expression of hSPP2 was restricted to specific tissues. Using immunofluorescence microscopy we also demonstrated that hSPP2 is localized to the endoplasmic reticulum (ER), suggesting that it functions in attenuating intracellular S1P signaling.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

DNA Construction-- pEGFP-C1 was purchased from Clontech. pcDNA3 HA4, a derivative of pcDNA3 (Invitrogen), was constructed to create a C-terminal hemagglutinin (HA)-tagged gene. BLAST searches using the hSPP1 sequence identified an EST clone (GenBankTM accession number BG696302) that contains an entire hSPP2 open reading frame (ORF) but lacks 45 bp of the 5' sequence. To obtain the entire hSPP2 cDNA, the primers 5'-GCCACCATGGCCGAGCTGCTGCGGAGCCTGCAGGATTCCCAGCTCGTCGCCCGCTTCCAGC-3' and 5'-TTTCAGGGTAATCCCAGAAACC-3' were used to amplify the hSPP2 cDNA from the EST clone BG696302. The amplified fragments were cloned into pGEM-T Easy (Promega) to generate the pCO64 plasmid. To construct a C-terminal HA-tagged gene, BamHI sites were created at both the 5' and 3' termini of hSPP2 by PCR amplification using primers 5'-GGATCCATGGCCGAGCTGCTGC-3' and 5'-GGGATCCGAGGGTAATCCC-3' from pCO64. The amplified DNA fragment was digested with BamHI and cloned into the BamHI site of pcDNA3 HA4 to generate pcDNA3 hSPP2-HA. The pcDNA3 mSPP1-HA plasmid, which encodes C-terminal HA-tagged mSPP1, was constructed as follows. The mSPP1 cDNA was amplified from the EST clone (GenBankTM accession number BG173194), which contains an entire mSPP1 ORF, using the primers 5'-AAAAAAGCTTGCGACCATGTCCCTGGGGGC-3' and 5'-AAGGATCCCCTTTATTGGTATCTCTTG-3'. The amplified DNA fragment was digested with HindIII and BamHI and cloned into the HindIII-BamHI site of pcDNA3 HA4 to generate pcDNA3 mSPP1-HA.

Cell Culture and Transfection-- HEK 293 cells were grown in Dulbecco's modified Eagle's medium containing 10% fetal calf serum supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin in a 5% CO2 incubator at 37 °C. HEK 293 cells were transfected with the indicated cDNA using LipofectAMINE Plus (Invitrogen).

Immunofluorescence Microscopy-- HEK 293 cells grown on coverslips and transfected with the indicated cDNAs were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS) at 37 °C for 10 min, permeabilized with 0.1% Triton X-100 in PBS, blocked with blocking solution (10 mg/ml bovine serum albumin in PBS), and incubated at 37 °C for 30 min with primary antibodies, anti-HA Y11 (Santa Cruz Biotechnology) at 1 µg/ml, or anti-KDEL antibody (StressGen Biotechnologies) at 4.8 µg/ml in blocking solution. After washing three times with PBS, the cells were incubated for 30 min with secondary antibody, Alexa 488-conjugated anti-rabbit or Alexa 594-conjugated anti-mouse antibody (Molecular Probes) diluted in blocking solution to 5 µg/ml. Coverslips were washed in PBS three times and in deionized water three times. Coverslips were then mounted with Mowiol 4-88 (Calbiochem) and observed under a fluorescence microscope.

Northern Blot Analysis-- Poly(A)+ RNA blots containing 1 µg of RNA from human tissues (Clontech) were used. For detection of hSPP2 mRNA, blots were probed with a 0.48-kb PstI-NcoI fragment of pcDNA3 hSPP2-HA that was labeled with [32P]dCTP by random priming. For detection of hSPP1 mRNA, a hSPP1 probe was prepared as follows. A 0.5-kb DNA fragment corresponding to the 3' region of hSPP1 ORF was amplified using the primers 5'-GCTGTCTTCTATCCATTTGTGGACC-3' and 5'-CTTCTCCATCAAGAGATACC-3' from the EST clone (GenBankTM accession number BI458997), which contains most of the hSPP1 ORF but lacks the 5' terminus. The amplified fragments were then gel-purified and labeled with [32P]dCTP by random priming. Hybridization was carried out in ExpressHyb buffer (Clontech) for 2 h at 68 °C.

In Vitro Phosphohydrolase Assay-- Cells suspended in buffer A (50 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 20% glycerol, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1× protease inhibitor mixture (CompleteTM, Roche Molecular Biochemicals)) were lysed by sonication. After centrifugation at 300 × g for 5 min at 4 °C, the supernatant was subjected to ultracentrifugation at 100,000 × g for 30 min at 4 °C. The resulting pellet was suspended in buffer A and used as a membrane fraction. Phosphohydrolase assays were performed by mixing the membrane fractions with 10 µM [4,5-3H]dihydro-S1P (50 Ci/mmol, American Radiolabeled Chemicals) or 10 µM [3-3H]S1P (23.5 Ci/mmol, PerkinElmer Life Sciences), each of which had been complexed with 1 mg/ml fatty acid-free bovine serum albumin (Sigma, A-6003) and then incubating the membrane fractions for 10 min at 37 °C. Lipids were extracted by successive additions of a 3.75-fold volume of chloroform/methanol/HCl (100:200:1, v/v), a 1.25-fold volume of chloroform and a 1.25-fold volume of 1% KCl with mixing. Phases were then separated by centrifugation, and the organic phase was recovered, dried, and dissolved in chloroform/methanol (2:1, v/v). The labeled lipids were resolved by thin layer chromatography (TLC) on Silica Gel 60 high performance TLC plates (Merck) with 1-butanol/acetic acid/water (3:1:1, v/v).

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Identification of hSPP2-- To identify a new S1P phosphohydrolase, the GenBankTM human EST data base was searched using the BLAST program for sequences similar to the hSPP1 sequence. We found several ESTs including BG696302, BM127455, BM830654, and AW779536 with high sequence homology to hSPP1. These ESTs contained different fragments but were derived from an identical cDNA, subsequently named human SPP2 (hSPP2). The ORF of hSPP2 encodes 399 amino acids with a molecular mass of 44.7 kDa (Fig. 1A). The hSPP2 sequence indicated 39.3% identity and 69.7% similarity to hSPP1. hSPP2 also shows significant homology to other SPP family members, whereas it is divergent from the LPP family (Fig. 1B). Although the N-terminal hydrophilic region of hSPP2 was shorter than that of hSPP1, the overall hydropathy profile of hSPP2 was very similar to that of hSPP1 (Fig. 1C), suggesting that the transmembrane structure of hSPP2 is the same as that of hSPP1. The TopPredII 1.1 program (19) predicts hSPP2 to be an integral membrane protein with as many as nine membrane-spanning segments. The three conserved motifs found in the superfamily of phosphatases, including several lipid phosphatases, were also present in hSPP2 (Fig. 1A).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence and hydropathic profile of hSPP2. A, alignment of amino acid sequences of hSPP1 and hSPP2. GenBankTM accession numbers are AJ293294 (hSPP1) and AF542512 (hSPP2). The alignment was generated using ClustalV (22) and BOXSHADE (Institute for Animal Health, Surrey, United Kingdom) programs. Black boxes indicate identical residues, and gray boxes show amino acid similarity. Underlined sequences indicate the three motifs found in a superfamily of phosphatases, including several lipid phosphatases, glucose-6-phosphatases, bacterial nonspecific acid phosphatases, and chloroperoxidase (15). B, dendrogram of the SPP and LPP families. Sequences from the SPP and LPP family members of human and yeast were aligned using ClustalW. GenBankTM accession numbers are AJ293294 (hSPP1), AF542512 (hSPP2), CAA89430 (Lcb3p), CAA82131 (Ysr3p), AF017116 (hLPP1), AF056083 (hLPP2), AF017786 (hLPP3), AAB64945 (Lpp1p), and AAB64475 (Dpp1p). C, hydropathy profiles of hSPP1 and hSPP2. The parameters used were from Kyte and Doolittle (23). Each point on the curve represents the hydropathy average of a 15-amino acid window.

Characterization of Phosphohydrolase Activity of hSPP2-- To investigate whether hSPP2 had S1P phosphohydrolase activity, HEK 293 cells were transiently transfected with a pcDNA3 hSPP2-HA encoding the C-terminal HA-tagged hSPP2 (hSPP2-HA). For comparison we also constructed a pcDNA3 mSPP1-HA that encodes the C-terminal HA-tagged mSPP1 (mSPP1-HA). Total cell lysates were prepared from HEK 293 cells, transfected with the respective plasmids, and separated by SDS-PAGE. This was followed by immunoblotting using anti-HA antibodies. A band with an apparent molecular mass of 33 kDa was specifically detected in hSPP2-HA-transfected cell lysates and was absent in vector-transfected cell lysates (Fig. 2, lanes 1 and 2). mSPP1-HA was detected as a band at 40 kDa (Fig. 2, lane 3). These mobilities were faster than the predicted molecular masses of hSPP2-HA (46.1 kDa) and mSPP1-HA (49.2 kDa).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Detection of hSPP2 by immunoblotting. HEK 293 cells were transfected with pcDNA3 HA4 (vector, lane 1), pcDNA3 hSPP2-HA (lane 2), and pcDNA3 mSPP1-HA (lane 3). 24 h after transfection total lysates were prepared from each cell line, and fixed amounts of protein (17 µg) were subjected to immunoblotting using anti-HA antibody. The asterisk indicates nonspecific background.

Using membrane fractions and [4,5-3H]dihydro-S1P we also performed an in vitro phosphohydrolase assay. In contrast to vector-transfected HEK 293 cells, which had low levels of activity, cells overproducing hSPP2-HA and mSPP1-HA exhibited a 6.3- and 11.5-fold increase in phosphohydrolase activity, respectively (Fig. 3, A and B, lanes 1 and 2). However, because mSPP1-HA was expressed 1.6 times more abundantly than hSPP2-HA (Fig. 2), the specific activity of hSPP2 against dihydro-S1P was similar to that of mSPP1.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   Phosphohydrolase activity and substrate specificity of hSPP2. A, samples from the same total lysates (60 µg of protein) used in Fig. 2 were ultracentrifuged, and the resulting membrane fractions were incubated with 10 µM [4,5-3H]dihydro-S1P at 37 °C for 10 min. Lipids were extracted and separated by TLC. Open bar, pcDNA3 HA4 (vector); closed bar, pcDNA3 hSPP2-HA; gray bar, pcDNA3 mSPP1-HA. Values relative to those exhibited by vector-transfected cells are shown. B, membrane fractions prepared from HEK 293 cells transfected with pcDNA3 HA4 (lanes 1 and 3) and pcDNA3 hSPP2-HA (lanes 2 and 4) were incubated with either 10 µM [4,5-3H]dihydro-S1P (lanes 1 and 2) or 10 µM [3-3H]S1P (lanes 3 and 4) at 37 °C for 10 min. Lipids were extracted and separated by TLC. Sph, sphingosine. C, membrane fractions prepared from HEK 293 cells transfected with pcDNA3 hSPP2-HA were incubated with 10 µM [4,5-3H]dihydro-S1P in the presence of 100 µM cold dihydro-S1P, S1P, LPA, PA, or glycerol 3-phosphate at 37 °C for 10 min. Lipids were extracted and separated by TLC. G3P, glycerol 3-phosphate.

To investigate the substrate specificity of hSPP2, the in vitro phosphohydrolase assay was performed using [3-3H]S1P. Similar to the results obtained using [4,5-3H]dihydro-S1P (Fig. 3B, lanes 1 and 2), cells overproducing hSPP2-HA exhibited an ~6-fold higher phosphohydrolase activity against [3-3H]S1P than did vector-transfected cells (Fig. 3B, lanes 3 and 4). Next, we performed a competition assay using [4,5-3H]dihydro-S1P and various excess cold lipids, including dihydro-S1P, S1P, LPA, PA, and glycerol 3-phosphate. S1P inhibited the dihydro-S1P phosphohydrolase activity as efficiently as dihydro-S1P (Fig. 3C). However, LPA, PA, and glycerol 3-phosphate had little inhibitory effect (Fig. 3C). These results indicated that hSPP2 is a phosphohydrolase specific to sphingoid base 1-phosphates.

A previous study demonstrated that SPP1s are Mg2+-independent phosphohydrolases (7). To examine the requirement of Mg2+ for the SPP2 activity, the S1P phosphohydrolase assay was performed in the presence of the metal chelator EDTA. The activity of SPP was not affected by 10 mM EDTA (Fig. 4). Furthermore, addition of 10 mM Mg2+ did not enhance the phosphohydrolase activity (data not shown). These results indicated that SPP2 is also a Mg2+-independent phosphohydrolase.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of EDTA, phosphatase inhibitors, and Triton X-100 on hSPP2 activity. Membrane fractions prepared from HEK 293 cells transfected with pcDNA3 HA4 (open bars) and pcDNA3 hSPP2-HA (closed bars) were incubated with 10 µM [3-3H]S1P in the presence of 10 mM EDTA, 10 mM NaF, 10 mM beta -glycerol phosphate, 10 mM sodium orthovanadate, or 0.2% Triton X-100 at 37 °C for 10 min. Lipids were extracted and separated by TLC. Values relative to those exhibited by vector-transfected cells with no treatment are shown.

We next examined the effects of various phosphatase inhibitors such as NaF, sodium orthovanadate, and beta -glycerol phosphate, as well as Triton X-100 on the SPP2 activity. Previous studies demonstrated that NaF, sodium orthovanadate, and Triton X-100 have strong inhibitory effects on SPP1 activity, whereas beta -glycerol phosphate is not effective (6, 7). Similar to SPP1, SPP2 was significantly inhibited by 10 mM sodium orthovanadate and 0.2% Triton X-100 but not by 10 mM beta -glycerol phosphate (Fig. 4). In contrast, 10 mM NaF, which efficiently inhibited the SPP1 activity, had no effect on the SPP2 activity (Fig. 4). Moreover, even 100 mM NaF did not inhibit the SPP2 activity (data not shown).

Immunofluorescent Localization of SPP2-- S1P can act both extracellularly, via cell surface Edg family receptors, and intracellularly. Therefore, it is important to distinguish whether hSPP2 plays a role in attenuating intracellular or extracellular S1P signaling. For this purpose, we performed an indirect immunofluorescence microscopic analysis to determine the localization of hSPP2. HEK 293 cells transiently transfected with a pcDNA3 hSPP2-HA were subjected to immunostaining with anti-HA antibody. Fig. 5A shows a reticular immunofluorescence staining pattern apparent in the perinuclear and cytosolic regions. This staining pattern was attributable to localization of hSPP2-HA in the ER, because it was superimposable upon the pattern of ER stained by an antibody against the ER retention signal, KDEL (Fig. 5A). This staining pattern of hSPP2 was similar to that of mSPP1 (Fig. 5B), which also co-localized with anti-KDEL antibody (data not shown). This result about the localization of mSPP1 is consistent with the recent report by Spiegel and co-workers (20). To examine the possibility that some fraction of hSPP2 is localized to the plasma membrane, we performed an immunofluorescence microscopic analysis using non-permeabilized cells. HEK 293 cells co-transfected with pEGFP-C1 and pcDNA3 hSPP2-HA were fixed and treated with or without Triton X-100, and hSPP2-HA was immunostained with anti-HA antibody. Permeabilized cells exhibiting green fluorescence protein fluorescence were stained with HA antibody (Fig. 5C), indicating that pEGFP-C1 and pcDNA3 hSPP2-HA were efficiently co-introduced. However, when the permeabilization step was omitted, cells exhibited only green fluorescence protein fluorescence and were not stained with HA antibody (Fig. 5D). This result indicated that permeabilization was essential for staining of hSPP2-HA. Thus, SPP2 may function in the ER to dephosphorylate intracellular S1P.


View larger version (53K):
[in this window]
[in a new window]
 
Fig. 5.   hSPP2 is localized to the ER. A, HEK 293 cells were transfected with pcDNA3 hSPP2-HA and were permeabilized, fixed, and then subjected to immunostaining. Cells were double-labeled with anti-HA (left panel) and anti-KDEL (middle panel) antibodies. In the merged images (right panel), green, red, and yellow indicate staining by anti-HA, staining by anti-KDEL, and co-localization, respectively. B, HEK 293 cells transfected with pcDNA3 mSPP1-HA were subjected to immunofluorescence microscopy using anti-HA antibody. C and D, HEK 293 cells co-transfected with pEGFP-C1 and pcDNA3 hSPP2-HA were fixed and treated with (C) or without (D) 0.1% Triton X-100. Cells were then subjected to immunostaining. Green fluorescence protein-labeling (left panels), hSPP2-HA staining (middle panels), and phase-contrast images (right panels) are shown. Bar, 10 µm.

Tissue Distribution of SPP2 mRNA Expression-- To compare the tissue distribution patterns of SPP1 and SPP2 mRNAs, we first examined the expression of hSPP1 mRNA in human tissues by Northern blotting. Similar to previously reported data for mSPP1 mRNA (6), hSPP1 mRNA was found to be ubiquitously expressed (Fig. 6A). A predominant 3.4-kb hSPP1 mRNA species was detected in all tissues, but the species varied in levels. The levels of the species were highest in placenta and kidney and lowest in peripheral blood and small intestine. A 1.0-kb transcript, which may be a spliced isoform, was detected only in placenta (Fig. 6A, lane 10). In contrast, the expression of hSPP2 mRNA was rather tissue-specific (Fig. 6B). We observed two mRNAs of 5.1 and 1.7 kb in size, and the 5.1-kb mRNA was detected in brain, heart, colon, kidney, small intestine, and lung but not in skeletal muscle, thymus, spleen, liver, placenta, and peripheral blood leukocyte (Fig. 6B). The expression levels of the 5.1-kb mRNA were highest in kidney and heart. The expression pattern of the 1.7-kb mRNA was similar but weaker than that of the 5.1-kb mRNA (Fig. 6B). Thus, the expression pattern of SPP2 was quite different from that for SPP1.


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 6.   Comparison of expression patterns of hSPP1 and hSPP2 in tissues. A 32P-labeled hSPP1 probe (A) or a hSPP2 probe (B) was hybridized to poly(A)+ RNA from 12 different human tissues (1 µg/lane). Lane 1, brain; lane 2, heart; lane 3, skeletal muscle; lane 4, colon; lane 5, thymus; lane 6, spleen; lane 7, kidney; lane 8, liver; lane 9, small intestine; lane 10, placenta; lane 11, lung; lane 12, peripheral blood leukocyte.

In summary, we identified a second S1P phosphohydrolase that shows similar activity, substrate specificity, and localization to previously identified SPP1s. Sequence and substrate specificity of hSPP2 confirm that SPP2 belongs to the SPP family. Although the expression patterns of SPP1 and SPP2 were quite different, both were expressed abundantly in kidney. It is unclear why two such S1P phosphohydrolases with similar enzymatic properties exist in the same tissue. However, yeast Saccharomyces cerevisiae also contains two sphingoid base 1-phosphate phosphatases, Lcb3p and Ysr3p, which also share similar enzyme activity and substrate specificity (8) and which are both localized to the ER (21). In synthetic complete medium the Delta lcb3 mutant, but not the Delta ysr3 mutant, was significantly protected from loss of viability after severe heat shock (9). However, the Delta ysr3 mutant showed a dramatic enhancement in survival when cultured in YPD medium (9). Moreover, transcription of YSR3 was up-regulated by heat shock (9). These results suggest that Lcb3p and Ysr3p are differentially regulated by growth and stress conditions. Therefore, it is possible that SPP1 and SPP2 are differentially regulated by unidentified conditions and have different roles in such conditions. Additional work will be needed to determine their specific function and regulation.

    ACKNOWLEDGEMENT

We thank A. Wada for the pcDNA3 HA-4 plasmid.

    FOOTNOTES

* This work was supported in part by Grant-in-aid for Scientific Research on Priority Areas (B) 12140201 from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and by Ono Pharmaceutical Co., Inc.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF542512.

Dagger To whom correspondence should be addressed. Tel.: 81-11-706-3970; Fax: 81-11-706-4986; E-mail: yigarash@pharm.hokudai.ac.jp.

Published, JBC Papers in Press, October 30, 2002, DOI 10.1074/jbc.M209514200

    ABBREVIATIONS

The abbreviations used are: S1P, sphingosine 1-phosphate; dihydro-S1P, dihydrosphingosine 1-phosphate; Edg, endothelial differentiation gene; PA, phosphatidate; LPA, lyso-phosphatidate; ER, endoplasmic reticulum; HA, hemagglutinin; ORF, open reading frame; PBS, phosphate-buffered saline; SPP, S1P phosphohydrolase; mSPP1, murine SPP1; hSPP1, human homolog of mSPP1; LPP, type 2 lipid phosphate phosphohydrolases; HEK, human embryonic kidney; hSPP2-HA, C-terminal HA-tagged hSPP2; mSPP1-HA, C-terminal HA-tagged mSPP1; EST, expressed sequence tag.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Igarashi, Y. (1997) J. Biochem. (Tokyo) 122, 1080-1087[Abstract]
2. Hla, T., Lee, M. J., Ancellin, N., Liu, C. H., Thangada, S., Thompson, B. D., and Kluk, M. (1999) Biochem. Pharmacol. 58, 201-207[CrossRef][Medline] [Order article via Infotrieve]
3. Spiegel, S., and Milstien, S. (2000) FEBS Lett. 476, 55-57[CrossRef][Medline] [Order article via Infotrieve]
4. Van Veldhoven, P. P., and Mannaerts, G. P. (1994) Biochem. J. 299, 597-601[Medline] [Order article via Infotrieve]
5. De Ceuster, P., Mannaerts, G. P., and Van Veldhoven, P. P. (1995) Biochem. J. 311, 139-146[Medline] [Order article via Infotrieve]
6. Mandala, S. M., Thornton, R., Galve-Roperh, I., Poulton, S., Peterson, C., Olivera, A., Bergstrom, J., Kurtz, M. B., and Spiegel, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7859-7864[Abstract/Free Full Text]
7. Le Stunff, H., Peterson, C., Thornton, R., Milstien, S., Mandala, S. M., and Spiegel, S. (2002) J. Biol. Chem. 277, 8920-8927[Abstract/Free Full Text]
8. Mao, C., Wadleigh, M., Jenkins, G. M., Hannun, Y. A., and Obeid, L. M. (1997) J. Biol. Chem. 272, 28690-28694[Abstract/Free Full Text]
9. Mandala, S. M., Thornton, R., Tu, Z., Kurtz, M. B., Nickels, J., Broach, J., Menzeleev, R., and Spiegel, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 150-155[Abstract/Free Full Text]
10. Waggoner, D. W., Gómez-Muñoz, A., Dewald, J., and Brindley, D. N. (1996) J. Biol. Chem. 271, 16506-16509[Abstract/Free Full Text]
11. Kai, M., Wada, I., Imai, S., Sakane, F., and Kanoh, H. (1997) J. Biol. Chem. 272, 24572-24578[Abstract/Free Full Text]
12. Dillon, D. A., Chen, X., Zeimetz, G. M., Wu, W. I., Waggoner, D. W., Dewald, J., Brindley, D. N., and Carman, G. M. (1997) J. Biol. Chem. 272, 10361-10366[Abstract/Free Full Text]
13. Roberts, R., Sciorra, V. A., and Morris, A. J. (1998) J. Biol. Chem. 273, 22059-22067[Abstract/Free Full Text]
14. Jasinska, R., Zhang, Q.-X., Pilquil, C., Singh, I., Xu, J., Dewald, J., Dillon, D. A., Berthiaume, L. G., Carman, G. M., Waggoner, D. W., and Brindley, D. N. (1999) Biochem. J. 340, 677-686[CrossRef][Medline] [Order article via Infotrieve]
15. Stukey, J., and Carman, G. M. (1997) Protein Sci. 6, 469-472[Abstract/Free Full Text]
16. Messerschmidt, A., and Wever, R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 392-396[Abstract/Free Full Text]
17. Toke, D. A., McClintick, M. L., and Carman, G. M. (1999) Biochemistry 38, 14606-14613[CrossRef][Medline] [Order article via Infotrieve]
18. Zhang, Q.-X., Pilquil, C. S., Dewald, J., Berthiaume, L. G., and Brindley, D. N. (2000) Biochem. J. 345, 181-184[CrossRef][Medline] [Order article via Infotrieve]
19. Claros, M. G., and von Heijne, G. (1994) Cabios 10, 685-686[Medline] [Order article via Infotrieve]
20. Le Stunff, H., Galve-Roperh, I., Peterson, C., Milstien, S., and Spiegel, S. (2002) J. Cell Biol. 158, 1039-1049[Abstract/Free Full Text]
21. Mao, C., Saba, J. D., and Obeid, L. M. (1999) Biochem. J. 342, 667-675[CrossRef][Medline] [Order article via Infotrieve]
22. Higgins, D. G., Bleasby, A. J., and Fuchs, R. (1992) Comput. Appl. Biosci. 8, 189-191[Abstract]
23. Kyte, J., and Doolittle, R. F. (1982) J. Mol. Biol. 157, 105-132[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.